Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials (Q35061280)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

0 references

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

meta-regression

1 reference

based on heuristic

inferred from title

object named as

Fabio Puglisi

4

0 references

object named as

Emilio Bria

2

0 references

Diana Giannarelli

object named as

Diana Giannarelli

14

0 references

Isabella Sperduti

object named as

Isabella Sperduti

6

0 references

Gianluigi Ferretti

12

object named as

Gianluigi Ferretti

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Federica Cuppone

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Vanja Vaccaro

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Alessandra Fabi

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Paolo Carlini

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michele Milella

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Cecilia Nisticò

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Michelangelo Russillo

10

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Paola Papaldo

11

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Matti Aapro

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Francesco Cognetti

15

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

12 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Journal of Experimental & Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

First-line chemotherapy with or without biologic agents for metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Meta-analyses of randomised clinical trials in oncology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Clearing the smoke on nicotine and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

Confidence intervals for the number needed to treat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

8 July 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

27 September 2018

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

27 September 2018

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

27 September 2018

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

27 September 2018

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

27 September 2018

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

27 September 2018

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

27 September 2018

Individualizing treatment decisions. The likelihood of being helped or harmed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3120715

27 September 2018

Interpreting Measures of Treatment Effect in Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-54

21 January 2018

Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569417

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab and Heart Failure Risk in Patients With Breast Cancer: A Thorn in the Side?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569417

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569417

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569417

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab treatment for solid tumors: boon or bust?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21569417

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1756-9966-30-54

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35061280&oldid=2197205337"